This study focuses on preventing venous thromboembolism (blood clots in veins) in patients undergoing total knee arthroplasty (knee replacement surgery). The research compares three different medications: a new drug called REGN7508 against two established treatments – apixaban and enoxaparin. REGN7508 is a new type of medicine that works by targeting specific blood clotting factors.
The purpose of the study is to determine how effective REGN7508 is at preventing blood clots after knee replacement surgery when compared to the standard treatments. The medication will be given either through an intravenous injection into a vein or as an injection under the skin. Some patients will receive apixaban tablets to take by mouth, while others will receive enoxaparin as an injection under the skin.
During the study, doctors will monitor patients for signs of blood clots and bleeding. They will also check how well the body tolerates the new medication and whether the body develops any response to it. The study will look for different types of blood clots, including deep venous thrombosis (blood clots in deep veins) and pulmonary embolism (blood clots in the lungs).



Bulgaria
Hungary
Latvia
Lithuania
Poland
Romania